Cardinal Health (CAH)
(Delayed Data from NYSE)
$94.10 USD
-0.36 (-0.38%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $94.12 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.10 USD
-0.36 (-0.38%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $94.12 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.
Insulet (PODD) Q4 Earnings, Revenues Top Mark, Margins Expand
by Zacks Equity Research
In the fourth quarter, Insulet (PODD) achieves the milestone of 425,000 estimated active global customers using Omnipod products.
Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down
by Zacks Equity Research
Myriad Genetics (MYGN) registers a strong testing volume improvement across all its businesses in the fourth quarter of 2023.
Alcon (ALC) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Alcon (ALC) delivers impressive performance across its franchises in the fourth quarter of 2023.
How to Find Top-Ranked Stocks to Buy in March
by Benjamin Rains
Exploring how investors can use the Filtered Zacks Rank 5 Stock Screen to help find potentially winning stocks to buy in March and throughout what looks set to be a strong 2024.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.
Quest Diagnostics' (DGX) New Pact to Reduce Food Insecurity
by Zacks Equity Research
Quest Diagnostics' (DGX) recent collaboration aims to advance food access and healthy eating habits for underserved communities.
GE HealthCare (GEHC), Biofourmis Partner to Boost At-Home Care
by Zacks Equity Research
GE HealthCare (GEHC) collaborates with Biofourmis to facilitate the patient's journey throughout the healthcare system and make the transition from hospital to home care easier.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Alcon (ALC) Faces Rising Expenses, Tough Competitive Scenario
by Zacks Equity Research
In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.
Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances
by Zacks Equity Research
Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.
Henry Schein (HSIC) Q4 Earnings Miss, Operating Margin Down
by Zacks Equity Research
Henry Schein (HSIC) posts lower-than-expected earnings and revenues in the fourth quarter of 2023.
Best Growth Stocks to Buy for February 27th
by Zacks Equity Research
POWL, CAH and TXT made it to the Zacks Rank #1 (Strong Buy) growth stocks list on February 27, 2023.
Momentum Monday: Bull Market Continues
by Ethan Feller
Want to start the week ahead of the pack? Check out Momentum Mondays
Here's Why You Should Buy Edward Lifesciences (EW) Stock Now
by Zacks Equity Research
Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.
Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
Penumbra's (PEN) Q4 revenues register year-over-year growth driven by robust U.S. thrombectomy sales.
ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software
by Zacks Equity Research
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Bruker's (BRKR) New Launches Drive Growth Amid FX Woes
by Zacks Equity Research
Bruker's (BRKR) revenues continue to be driven by the strength of end markets, including academic and government, and industrial.
Philips' (PHG) New Innovation to Boost Radiation-Free Imaging
by Zacks Equity Research
Philips (PHG) announces its latest LumiGuide imaging technology, which is likely to pave the way for new radiation-free procedures. It will prove beneficial for complex aortic surgeries.
Here's Why Investors Should Hold Labcorp (LH) Stock for Now
by Zacks Equity Research
Targeted development in high-growth areas and strategic partnerships bode well for Labcorp (LH).
Charles River (CRL) Forges Collaboration With Wheeler Bio
by Zacks Equity Research
Charles River (CRL) and Wheeler Bio join forces to accelerate the journey from discovery and CMC development to manufacturing.
Amedisys' (AMED) Q4 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q4 performance.
BD (BDX), Camtech Health Unite to Aid Cervical Cancer Screening
by Zacks Equity Research
BD (BDX) collaborates with Camtech Health to improve the rate of cervical cancer screening in Singapore by offering women an option to self-collect samples in the privacy of their own homes.
Lantheus (LNTH) Q4 Earnings Surpass Estimates, Gross Margin Up
by Zacks Equity Research
Lantheus' (LNTH) robust segmental revenues drive its fourth-quarter performance.